Prostate cancer (PCa) remains the second most commonly diagnosed malignant cancer among men worldwide.[1] In the United States, PCa accounts for 34 500 deaths annually, almost from advanced disease.[2] The primary treatment for men with advanced PCa is androgen deprivation therapy (ADT), in which androgen receptor (AR) signaling is inhibited. This evidence concerns the gene AR and prostate carcinoma.